Taxim 125 mg Injection is a prescription antibiotic containing FDA-approved Cefotaxime (125 mg). It is used in hospital settings for the treatment of bacterial infections of the lungs, ears, throat, urinary tract, respiratory tract, and blood that require injectable therapy, particularly when rapid and reliable action is needed.
Cefotaxime works by inhibiting bacterial cell wall synthesis, leading to the destruction of infection-causing bacteria. Its bactericidal action is effective against a wide range of gram-positive and gram-negative organisms.
One of its key advantages is its ability to penetrate the central nervous system, making it especially useful in treating infections involving the brain and spinal cord. Additionally, it is converted in the body into an active metabolite that further enhances its antibacterial activity.
The 125 mg strength is commonly used in neonates and children, where precise, weight-based dosing is required.
Taxim 125 mg Injection is manufactured by Alkem Laboratories Ltd and should be stored below 25°C, protected from light, and reconstituted solutions should be used within the recommended timeframe.
Common side effects of Cefotaxime include injection site reactions, rash, diarrhea, and mild changes in liver enzyme levels. Inform a doctor about any history of antibiotic allergies, kidney or liver conditions, or use of other medications before starting treatment.
Taxim 125 mg Injection inhibits the synthesis of the bacterial cell wall, making it effective against a broad range of serious infections. Its reliable distribution in body tissues, including the central nervous system, along with additional activity from its active metabolite, enhances its overall clinical effectiveness and makes it suitable for both adults and pediatric patients.
It is commonly used to treat infections such as:
Taxim 125 mg Injection is a prescription medication for clinical use only and is administered under the supervision of a qualified healthcare professional. General administration considerations include:
Taxim Injection is available in multiple strength alternatives at Cheap Medicine Shop, including:
| Taxim 250 mg Injection | $2.40/injection |
| Taxim 500 mg Injection | $3.16/injection |
Like any medication, Taxim 125 mg Injection can cause some side effects that are generally mild and resolve with continued therapy or after the course is completed. However, consult a healthcare professional if they persist or worsen:
Liver Disease
Taxim 125 mg Injection should be used with caution in patients with liver disease. While Cefotaxime undergoes partial liver metabolism, impaired liver function can affect the clearance of the medicine or liver enzymes. Inform a doctor of any liver conditions before treatment is initiated.
Kidney Impairment
Individuals with kidney disease should use Cefotaxime Injection with caution. Cefotaxime and its metabolite are primarily eliminated via the kidneys, and impaired function can lead to accumulation and increased risk of adverse effects. Always consult a doctor before use to ensure safety.
Pregnant and Breastfeeding women
Taxim 125 mg Injection should be used during pregnancy only when clearly necessary and under medical supervision. While cephalosporins are generally considered among the safer antibiotics in pregnancy, the safety of Cefotaxime in human pregnancies has not been completely established. Cefotaxime also passes into breast milk. So, women should stop breastfeeding or consult a doctor before use to evaluate whether continuing therapy is appropriate for the nursing infant.
Avoid
Do not use Taxim 125 mg Injection in patients with known hypersensitivity to Cefotaxime, any cephalosporin antibiotic, or any component of the formulation. Exercise caution in patients with documented penicillin allergy, as cross-reactivity with cephalosporins, though uncommon, is possible. Inform a doctor of all current medications, particularly Aminoglycosides, nephrotoxic medicines, and loop diuretics, before initiating therapy to identify potential interactions.
Yes, allergic reactions are possible with Cefotaxime, ranging from mild skin rashes to rare but serious anaphylactic reactions. Patients with a known allergy to cephalosporins or penicillins are at higher risk. Inform a doctor of any antibiotic allergies before administration, and seek immediate medical attention if a severe reaction occurs.
In most bacterial infections, clinical improvement in fever, pain, and systemic signs is typically observed within 48 to 72 hours of using Taxim Injection. The full prescribed course must always be completed regardless of how quickly symptoms improve.
Yes, Taxim Injection is safe for children when prescribed by a doctor. The 125 mg strength allows precise weight-based dose calculation for younger patients. A pediatrician will determine the appropriate dose and frequency based on the child's age, weight, kidney function, and the severity of the infection.
Yes, Cefotaxime is a standard treatment option for Septicemia and Sepsis caused by susceptible gram-positive and gram-negative organisms. Its rapid bactericidal activity and ability to achieve reliable plasma concentrations via the intravenous route make it a clinically important choice for severe systemic infections, often used in combination with other antibiotics.
Yes, Cefotaxime is effective and is prescribed for the treatment of uncomplicated Gonorrhea, particularly when oral antibiotics are not suitable or when the organism has demonstrated resistance to other first-line agents. A doctor will confirm susceptibility and determine the appropriate dose and route based on clinical presentation.
Yes, diarrhea is a possible side effect of Cefotaxime, typically mild and transient. If diarrhea is severe, prolonged, or accompanied by blood or mucus, seek prompt medical attention to avoid complications.
As a third-generation cephalosporin, Cefotaxime offers significantly enhanced gram-negative coverage and greater beta-lactamase stability compared to first-generation agents such as Cefalexin. It also penetrates the blood-brain barrier to treat CNS infections, which is a capability that first-generation cephalosporins lack.